BD SurePath Direct to Slide (DTS) cervical cytology: Migrating the benefits of liquid-based cytology to low-resource settings.

SurePath cervical cytology cytological techniques early detection of cancer equipment and supplies reproducibility of results uterine cervical neoplasms

Journal

American journal of clinical pathology
ISSN: 1943-7722
Titre abrégé: Am J Clin Pathol
Pays: England
ID NLM: 0370470

Informations de publication

Date de publication:
24 Jun 2024
Historique:
received: 25 01 2024
accepted: 08 05 2024
medline: 24 6 2024
pubmed: 24 6 2024
entrez: 24 6 2024
Statut: aheadofprint

Résumé

The benefits of liquid-based cytology (LBC) in routine cervical cancer screening are often associated with the availability of instrumented platforms and economic considerations. A low-cost alternative to LBC in low-volume settings remains an unmet need. A multisite evaluation of the BD SurePath (SurePath) LBC Direct to Slide (DTS) method was conducted. The DTS preparations were evaluated across 3 sites. Cytology features for DTS preparation included predetermined thresholds for total cellularity, cell distribution, cellular preservation, and stain quality. Rare event detection was evaluated using SiHa cells spiked into pools from negative cytology specimens. Concordance between Bethesda classification results was evaluated for SurePath LBC and DTS methods using routinely collected SurePath specimens in a split-sample study design. The DTS specimens met criteria for total cellularity, cell distribution, cellular preservation, and stain quality in more than 98% of all cases. Rare event detection was observed with an average detection of 5 SiHa cells per 2 mL of specimen. Concordant cervical cytology classifications were observed between SurePath LBC and DTS methods. The results demonstrate that the DTS process is suitable for routine cervical cytology evaluation. The procedure is reproducible and detected abnormal cervical cells in concordance with standard SurePath LBC preparation.

Identifiants

pubmed: 38913880
pii: 7698052
doi: 10.1093/ajcp/aqae068
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Becton, Dickinson and Company

Informations de copyright

© American Society for Clinical Pathology, 2024.

Auteurs

Douglas P Malinowski (DP)

Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, US.

Ryan Callaghan (R)

Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, US.

Clark Whitehead (C)

Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, US.

Romana Nelson (R)

Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, US.

Lisa Allen (L)

Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, US.

Dondrea Purnell (D)

Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, US.

Adriann Taylor (A)

Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, US.

Didier Morel (D)

Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, US.

Aisha Dhewar (A)

Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, US.

Vanessa Soh Chai-Hong (VS)

National University Hospital, Singapore.

Goh Giap-Hean (G)

National University Hospital, Singapore.

Soo-Yong Tan (SY)

National University Hospital, Singapore.

Sagar Tapas (S)

Lifeline Labs, New Delhi, India.

Jeffrey Andrews (J)

Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, MD, US.

Classifications MeSH